Critical factors for successful multiplex PCR

2-part series - Advantages of using Multiplex PCR in simultaneous detection of nucleic acid targets 

Part 1. Critical factors for successful multiplex PCR

Multiplex end-point PCR is a powerful tool for genotyping and many other applications. The ability to amplify and detect several DNA targets in the same reaction offers many benefits. It enables generation of more data from minimal amounts of sample material, which is especially beneficial in procedures involving limited and precious sample material. It also offers the opportunity to run internal controls in every reaction, thus increasing the overall reliability of data acquisition. Most importantly of course, switching PCR-based routine lab testing to multiplex PCR offers the opportunity to substantially save on time, materials and cost.

QIAGEN’s multiplex PCR chemistry is optimized for reliable amplification of many different templates with high variability in copy numbers. Thus, it enables very quick establishment of a new lab routine and instant success for your multiplex PCR strategy.

There are a set of critical factors that should be considered when planning and performing this type of PCR. These recommendations will be discussed in detail in the webinar. Additionally, our multiplex PCR chemistry has recently been gaining increasing popularity among scientists who are utilizing it for their next-generation sequencing workflows. We will also briefly discuss this topic.

Laura Alina Mohr, M.Sc.

Laura Alina Mohr joined QIAGEN in 2015. She received her Master’s Degree in Chemical Biology at the Technical University Dortmund in Germany. During this time, she was involved in Systemic Cell Biology research at the prestigious Max Planck Institute. Before joining QIAGEN, Laura Alina worked at the Scripps Research Institute, San Diego, where she first focused on DNA damage/repair pathways and telomere biology. Later, she joined the Muscle Development, Aging and Regeneration program at the Sanford Burnham Prebys Medical Discovery Institute. At QIAGEN she is interested in gene expression profiling focusing on various biological pathways, e.g. cancer research and neurodegeneration.